1. Method Development for Reversed-Phase Separations of Peptides: A Rational Screening Strategy for Column and Mobile Phase Combinations with Complementary Selectivity
- Author
-
Field, Jennifer K., Bruce, James, Buckenmaier, Stephan, Cheung, Ming Yui, Euerby, Melvin R., Haselmann, Kim F., Lau, Jesper F., Stoll, Dwight, Sylvester, Maria, Thogersen, Henning, and Petersson, Patrik
- Subjects
Novo Nordisk A/S ,Mass spectrometry -- Analysis ,Liquid chromatography -- Analysis ,Peptides -- Analysis ,Substance abuse -- Analysis ,Pharmaceutical industry -- Analysis ,Chemistry ,Science and technology - Abstract
This review article summarizes the results obtained from the combined efforts of a joint academic and industrial initiative to solve the real-life challenge of determining low levels of peptide-related impurities (typically 0.05-1% of the drug substance) in the presence of the related biologically active peptide at a high concentration. A rational screening strategy for pharmaceutical^ important peptides has been developed that uses combinations of reversed-phase ultrahigh-pressure liquid chromatography (UHPLC) columns and mobile phases that exhibit complementary reversed-phase chromatographic selectivity using either UV- or mass spectrometry (MS)-compatible conditions. Numerous stationary and mobile phases were categorized using the chemometric tool of principal component analysis (PCA), employing a novel characterization protocol utilizing specifically designed peptide probes. This was successfully applied to the development of a strategy for the detection of impurities (especially isomers) in peptide drug substances using two-dimensional liquid chromatography coupled with MS detection (2D-LC-MS). KEY POINTS * A column and mobile phase reversed-phase chromatography characterization protocol employing relevant peptide probes is described. * Principal component analysis of the characterization database allowed the identification of column and mobile phase combinations with differing or similar chromatographic selectivity., The movement from small molecule-based new drug entities to larger and more complex biomolecules, such as peptides and proteins, has increased in recent years (1,2). This has led to a [...]
- Published
- 2022